Improved	B:C0184511
diagnostic	O
yield	O
of	O
neuromuscular	O
disorders	I:C0027868
applying	O
clinical	O
exome	O
sequencing	I:C3640077
in	O
patients	O
arising	O
from	O
a	O
consanguineous	O
population	O
.	O

Improved	O
diagnostic	O
yield	O
of	O
neuromuscular	B:C0027868
disorders	I:C0027868
applying	O
clinical	O
exome	O
sequencing	I:C3640077
in	O
patients	O
arising	O
from	O
a	O
consanguineous	O
population	O
.	O

Improved	O
diagnostic	O
yield	O
of	O
neuromuscular	O
disorders	I:C0027868
applying	O
clinical	O
exome	B:C3640077
sequencing	I:C3640077
in	O
patients	O
arising	O
from	O
a	O
consanguineous	O
population	O
.	O

Improved	O
diagnostic	O
yield	O
of	O
neuromuscular	O
disorders	I:C0027868
applying	O
clinical	O
exome	O
sequencing	I:C3640077
in	O
patients	O
arising	O
from	O
a	O
consanguineous	O
population	B:C1257890
.	O

Neuromuscular	B:C0027868
diseases	I:C0027868
(	O
Neuromuscular	O
diseases	I:C0027868
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	O
affecting	O
muscles	O
,	O
nerves	O
and	O
neuromuscular	O
junctions	I:C0027869
.	O

Neuromuscular	O
diseases	I:C0027868
(	O
Neuromuscular	B:C0027868
diseases	I:C0027868
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	O
affecting	O
muscles	O
,	O
nerves	O
and	O
neuromuscular	O
junctions	I:C0027869
.	O

Neuromuscular	O
diseases	I:C0027868
(	O
Neuromuscular	O
diseases	I:C0027868
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	B:C0012634
affecting	O
muscles	O
,	O
nerves	O
and	O
neuromuscular	O
junctions	I:C0027869
.	O

Neuromuscular	O
diseases	I:C0027868
(	O
Neuromuscular	O
diseases	I:C0027868
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	O
affecting	O
muscles	B:C0026845
,	O
nerves	O
and	O
neuromuscular	O
junctions	I:C0027869
.	O

Neuromuscular	O
diseases	I:C0027868
(	O
Neuromuscular	O
diseases	I:C0027868
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	O
affecting	O
muscles	O
,	O
nerves	B:C0027740
and	O
neuromuscular	O
junctions	I:C0027869
.	O

Neuromuscular	O
diseases	I:C0027868
(	O
Neuromuscular	O
diseases	I:C0027868
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	O
affecting	O
muscles	O
,	O
nerves	O
and	O
neuromuscular	B:C0027869
junctions	I:C0027869
.	O

Their	O
overlapping	O
phenotypes	O
and	O
heterogeneous	O
genetic	O
nature	O
have	O
created	O
challenges	O
in	O
diagnosis	B:C0011900
which	O
calls	O
for	O
the	O
implementation	O
of	O
massive	O
parallel	I:C2936622
sequencing	I:C2936622
as	O
a	O
candidate	O
strategy	O
to	O
increase	O
the	O
diagnostic	O
yield	O
.	O

Their	O
overlapping	O
phenotypes	O
and	O
heterogeneous	O
genetic	O
nature	O
have	O
created	O
challenges	O
in	O
diagnosis	O
which	O
calls	O
for	O
the	O
implementation	O
of	O
massive	B:C2936622
parallel	I:C2936622
sequencing	I:C2936622
as	O
a	O
candidate	O
strategy	O
to	O
increase	O
the	O
diagnostic	O
yield	O
.	O

In	O
this	O
study	B:C2603343
,	O
total	O
of	O
45	O
patients	O
,	O
mostly	O
offspring	O
of	O
consanguineous	O
marriages	O
were	O
examined	O
using	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
.	O

In	O
this	O
study	O
,	O
total	O
of	O
45	O
patients	O
,	O
mostly	O
offspring	O
of	O
consanguineous	O
marriages	O
were	O
examined	O
using	O
whole	B:C3640077
exome	I:C3640077
sequencing	I:C3640077
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	B:C3816499
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	B:C0678941
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	B:C0027868
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	B:C0017337
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	B:C0017337
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	B:C1413113
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	B:C1413589
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	B:C1413591
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	B:C1414083
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	B:C1414209
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	B:C1414612
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	B:C1415076
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	B:C2829592
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	B:C1416776
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	B:C1416877
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	B:C1418643
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	B:C1419778
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	B:C1420005
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	B:C1420006
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	B:C1424736
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	B:C1420827
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	B:C3816499
variants	O
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	B:C0678941
were	O
detected	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	I:C0678941
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	B:C0442726
.	O

Today	O
,	O
the	O
advantage	O
of	O
whole	B:C3640077
exome	I:C3640077
sequencing	I:C3640077
in	O
clinical	O
diagnostic	I:C0332140
strategies	O
of	O
heterogeneous	O
disorders	I:C1858576
is	O
clear	O
.	O

Today	O
,	O
the	O
advantage	O
of	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
in	O
clinical	B:C0332140
diagnostic	I:C0332140
strategies	O
of	O
heterogeneous	O
disorders	I:C1858576
is	O
clear	O
.	O

Today	O
,	O
the	O
advantage	O
of	O
whole	O
exome	I:C3640077
sequencing	I:C3640077
in	O
clinical	O
diagnostic	I:C0332140
strategies	O
of	O
heterogeneous	B:C1858576
disorders	I:C1858576
is	O
clear	O
.	O

In	O
this	O
cohort	B:C0599755
,	O
a	O
diagnostic	O
yield	O
of	O
73.3	O
%	O
was	O
achieved	O
which	O
is	O
quite	O
high	O
compared	O
to	O
the	O
overall	O
reported	O
diagnostic	O
yield	O
of	O
25	O
%	O
to	O
50	O
%	O
.	O

This	O
could	O
be	O
explained	O
by	O
the	O
consanguineous	O
background	O
of	O
these	O
patients	O
and	O
is	O
another	O
strong	O
advantage	O
of	O
offering	O
clinical	O
exome	B:C3640077
sequencing	I:C3640077
in	O
diagnostic	O
laboratories	O
,	O
especially	O
in	O
populations	O
with	O
high	O
rate	O
of	O
consanguinity	O
.	O

This	O
could	O
be	O
explained	O
by	O
the	O
consanguineous	O
background	O
of	O
these	O
patients	O
and	O
is	O
another	O
strong	O
advantage	O
of	O
offering	O
clinical	O
exome	O
sequencing	I:C3640077
in	O
diagnostic	O
laboratories	B:C0022877
,	O
especially	O
in	O
populations	O
with	O
high	O
rate	O
of	O
consanguinity	O
.	O

This	O
could	O
be	O
explained	O
by	O
the	O
consanguineous	O
background	O
of	O
these	O
patients	O
and	O
is	O
another	O
strong	O
advantage	O
of	O
offering	O
clinical	O
exome	O
sequencing	I:C3640077
in	O
diagnostic	O
laboratories	O
,	O
especially	O
in	O
populations	B:C1257890
with	O
high	O
rate	O
of	O
consanguinity	O
.	O

This	O
could	O
be	O
explained	O
by	O
the	O
consanguineous	O
background	O
of	O
these	O
patients	O
and	O
is	O
another	O
strong	O
advantage	O
of	O
offering	O
clinical	O
exome	O
sequencing	I:C3640077
in	O
diagnostic	O
laboratories	O
,	O
especially	O
in	O
populations	O
with	O
high	O
rate	O
of	O
consanguinity	B:C0009789
.	O

